PubRank

Donald A Mahler

Author PubWeight™ 33.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007 5.01
2 An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012 3.62
3 Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010 2.56
4 Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014 2.00
5 An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015 1.63
6 Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 2007 1.56
7 Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006 1.30
8 Measuring the effects of COPD on the patient. Respir Med 2005 1.13
9 Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003 1.02
10 Inflammation in COPD: implications for management. Am J Med 2012 1.00
11 Recent advances in dyspnea. Chest 2015 0.99
12 Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD. Int J Chron Obstruct Pulmon Dis 2012 0.94
13 Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest 2004 0.94
14 Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med 2014 0.92
15 Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med 2011 0.86
16 Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015 0.85
17 Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD 2011 0.81
18 Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. Eur Respir J 2013 0.81
19 Advantages of endurance treadmill walking compared with cycling to assess bronchodilator therapy. Chest 2009 0.78
20 Prospective Use of Descriptors of Dyspnea to Diagnose Common Respiratory Diseases. Chest 2015 0.77
21 Perceptual and physiologic responses during treadmill and cycle exercise in patients with COPD. Chest 2008 0.77
22 One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest 2014 0.76
23 Is physical activity anti-inflammatory on the airways? Thorax 2007 0.75
24 More is better once again! J Cardiopulm Rehabil 2005 0.75
25 Response. Chest 2014 0.75
26 Are you fluent in the language of dyspnea? Chest 2008 0.75
27 Hit the dyspnea target! J Cardiopulm Rehabil 2003 0.75
28 It's about time--directing our attention toward modifying the course of COPD. Respir Med 2008 0.75